A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

BACKGROUND: Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb against IL-6, was evaluated in a three-part phase I/II study in patients with progressive metastatic RCC. METHODS: In part 1, 11 patients recei...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rossi, J-F, Négrier, S, James, N D, Kocak, I, Hawkins, R, Davis, H, Prabhakar, U, Qin, X, Mulders, P, Berns, B
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2967052/
https://ncbi.nlm.nih.gov/pubmed/20808314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605872
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados